My Fountain of Youth Forum - By using our website and services, you confirm your understanding of and agreement to our Terms of Service.

Urine therapy reverses blood clots... the best blood thinner on the market comes from human urine called Urokinase (also known as urokinase-type plasminogen activator or uPA) is a "clot-busting" drug (thrombolytic agent) that was historically and is still partially derived from human urine.

Yes, Urokinase is a "clot-busting" drug (thrombolytic agent) that was historically and is still partially derived from human urine.

Here are the key details regarding this medication:
Origin: The enzyme was first identified in human urine in 1947 and purified from it in 1952, which is how it earned its name "urinary kinase". While modern production methods also utilize human neonatal kidney cells grown in culture, human urine remains a source.

Function: Urokinase is not technically a "blood thinner" (anticoagulant) that stops new clots from forming; it is a thrombolytic (clot dissolver). It works by activating plasminogen, converting it to plasmin, which breaks down fibrin—the structural backbone of blood clots.

Uses: It is used intravenously to treat severe, life-threatening blood clots, particularly massive pulmonary embolisms, as well as to clear blocked intravenous (IV) catheters.

Brand Names/Status: It has been sold under brand names such as Abbokinase and Kinlytic. In the United States, urokinase has had limited availability or was withdrawn by certain manufacturers in the past, though it remains in use in other regions.

Risks: Because it is derived from human sources, it carries a small risk of transmitting infections, although donated materials are tested. Its primary danger is causing serious or fatal bleeding, as it does not distinguish between dangerous clots and "good" clots that mend blood vessels.

National Institutes of Health (.gov)

While newer drugs, such as tissue-type plasminogen activators (tPA), are more common today due to their ability to target clots more specifically, urokinase remains a significant, though less common, agent in thromboembolic care.